Vaccine Must Have At Least 50% Efficacy In Phase 3 Trials: Drug Authority

The Drugs Controller General of India (DCGI) has issued a new set of guidelines, focusing on safety, immunogenicity and efficacy parameters for pharma giants who are developing COVID-19 vaccines.